This biotechnology company headquartered in Vienna specialises in skin diseases. Origimm's most important product is a vaccine-based immunotherapy against acne which is currently in the test phase. According to Sanofi, Origimm complements its own research platform for mRNA vaccines.
Following its termination of diabetes research, Sanofi considers the immune business to be one of its main pillars. Sanofi aims to more than double its vaccine sales by the end of the decade. Its focus will be on vaccines against the flu and meningitis as well as polio and booster shots. Sanofi expects to have ten vaccines in clinical studies by the year 2025, of which six will be mRNA vaccines.
Continue reading and learn more about life sciences research in Austria!